Angiogenesis in Head and Neck Cancer: A Review of the Literature

Table 1

Clinical trials with antiangiogenic drugs.

Regimen	Setting	No. of patients	Results
Sunitinib [42]	Recurrent/metastatic (first line)	22	RDC 33% (terminated after interim analysis)
Sunitinib [43]	Recurrent/metastatic (first line)	17	Terminated for lack of efficacy
Sunitinib [44]	Recurrent/metastatic (platinum refractory)	38	RDC 50%. mPFS 2 months, mOS 4 months
Sorafenib [45]	Recurrent/metastatic (second line)	28	ORR 37%. mOS 4.2 months
Sorafenib [46]	Recurrent/metastatic (first line)	41	mPFS 4 months. Estimated OS 9 months
Erlotinib+bevacizumab [47]	Recurrent/metastatic (first/second line)	48	RR 15%. mPFS 4.1 months. mOS 7.1 months
Bevacizumab+fluorouracil+hydroxyurea and radiotherapy [54]	Locally advanced relapsed or poor prognosis newly diagnosed	43	mOS 10.7 months
Carboplatin+paclitaxel+5 fluororuracil+ bevacizumab followed by radiotherapy +paclitaxel+bevacizumab+erlotinib [68]	Locally advanced (first line)	60	ORR 77%. 18 months PFS 85%, 18 months OS 87%
Bevacizumab+cisplatin+IMRT [69]	Locally advanced (first line)	42	Locoregional control rate 100%. Estimated 1 year PFS 83%; estimated 1 year OS 88%

RDC: rate of disease control; mPFS: median progression-free survival; mOS: median overall survival; ORR: overall response rate.